P2, N=35, Active, not recruiting, Washington University School of Medicine | Trial completion date: Sep 2026 --> Mar 2027 | Trial primary completion date: Mar 2026 --> Sep 2026

P2, N=160, Recruiting, Avalyn Pharma Inc. | Not yet recruiting --> Recruiting | N=64 --> 160

P2, N=40, Recruiting, National Cancer Centre, Singapore | Trial completion date: Dec 2027 --> Dec 2028 | Trial primary completion date: Dec 2025 --> Dec 2026

After prior ICI exposure, VEGFR-TKIs continue to represent the treatment backbone, while later-line options such as hypoxia-inducible factor-2α (HIF-2α) inhibitors and lenvatinib-everolimus further expand sequencing possibilities. Randomized studies have not shown consistent benefit for routine ICI rechallenge in unselected populations. Overall, advanced ccRCC management requires structured individualization, while validated predictive biomarkers and prospective sequencing data remain important unmet needs.

Furthermore, the combination treatment induced G2/M phase cell cycle arrest by modulating the ATM-Chk2 signaling pathway. This study demonstrates that the combination of lenvatinib and BP represents a promising therapeutic strategy for CRC by enhancing apoptosis and cell cycle arrest through ROS-mediated DNA damage.

Patchouli alcohol (PA) is a tricyclic sesquiterpene derived from Pogostemon cablin, and the present study evaluated the antihepatoma capacity of PA and described a potential strategy for its combination with sorafenib (SOR) in vitro and in vivo...On the whole, PA alone or in combination with SOR exhibited markedly improved therapeutic efficacy in HCC by blocking AR-mediated and multiple other signaling pathways. Therefore, this study provides an experimental basis for the evaluation of PA as an alternative drug (alone or in combination) for the treatment of HCC.

Compound 9a displayed strong inhibitory activity against VEGFR-2, with an IC50 value of 0.23 ± 0.03 μM, comparable to that of sorafenib...Docking within the VEGFR-2 active site supported the biological findings by revealing promising binding interactions. Besides, ADME analysis supports the design strategy and suggests that these derivatives possess promising pharmacokinetic properties.

FSD1L is a novel oncogenic driver in HCC that is selectively enriched in metastatic and lenvatinib-resistant contexts. It activates the WNT/β-catenin pathway to regulate HCC proliferation, EMT and lenvatinib resistance. FSD1L holds promise as a dual biomarker for diagnosis/prognosis and a potential therapeutic target for lenvatinib resistance in HCC.

L-serine supplementation or dasatinib/quercetin administration to eliminate senescent cells alleviates both CS-induced neurobehaviors and peripheral hyperglycemia. Together, these findings reveal that HK2 in amygdaloid astrocytes mediates CS-induced neurobehaviors and hyperglycemia.

This case highlights a rare cytogenetic abnormality in CML characterized by acquired pericentric inversion of the derivative chromosome 9 associated with BCR and ABL1 codeletion. Such complex rearrangements likely reflect clonal evolution and may be associated with suboptimal response to first line imatinib therapy. Accurate discrimination between constitutional and acquired inv(9), together with detailed assessment of derivative chromosome 9 integrity, is essential for prognostic stratification. Comprehensive cytogenetic and molecular analyses remain critical for identifying uncommon secondary abnormalities that may influence therapeutic response and clinical outcome in CML.

P2, N=40, Completed, Asan Medical Center | Recruiting --> Completed

P2, N=101, Recruiting, National Cancer Institute (NCI) | Trial completion date: Jun 2026 --> Sep 2026 | Trial primary completion date: Jun 2026 --> Sep 2026